Welcome to our dedicated page for Lexeo Therapeutics SEC filings (Ticker: LXEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexeo Therapeutics, Inc. (LXEO) SEC filings page on Stock Titan aggregates the company’s public regulatory documents from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret key disclosures. As a Nasdaq-listed, clinical stage genetic medicine company, Lexeo uses filings such as Forms 8-K, 10-Q, and 10-K to report material events, financial results, and risk factors related to its gene therapy programs and corporate activities.
In its 8-K filings, Lexeo has reported items such as quarterly financial results, equity financings through underwritten public offerings and concurrent private placements, material definitive agreements like underwriting and securities purchase agreements, and registration rights agreements related to pre-funded warrants. The company also uses 8-Ks to furnish press releases that provide interim clinical and regulatory updates for its lead programs, LX2006 in Friedreich ataxia (FA) cardiomyopathy and LX2020 in PKP2-associated arrhythmogenic cardiomyopathy.
Filings also describe Lexeo’s interactions with the FDA, including feedback on potential accelerated approval pathways, participation of LX2006 in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot program, and regulatory designations such as Breakthrough Therapy, RMAT, Orphan Drug, Rare Pediatric Disease, and Fast Track. Corporate governance matters, executive appointments, compensation arrangements, and stockholder meeting results are likewise documented in SEC reports.
On Stock Titan, investors can review these filings alongside AI-generated highlights that summarize complex sections, helping to identify information on clinical development plans, capital structure changes, and other material disclosures. Real-time updates from EDGAR, combined with structured access to forms such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports, support deeper analysis of Lexeo’s regulatory and financial reporting history.
Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $5.81 per share and expire on April 27, 2036. They vest in equal annual installments over three years, so the award becomes fully exercisable on the third anniversary of the grant date, subject to her continuous service with the company. After this grant, she holds options for 50,000 underlying shares directly.
Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino has filed a Form 3 insider ownership report. The provided data lists her status as a director of the company and shows no reported transactions, share holdings, or derivative securities in this filing excerpt.
Lexeo Therapeutics, Inc. is holding a fully virtual 2026 annual stockholders meeting on June 25, 2026, at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/LXEO2026. Stockholders will vote on electing three Class III directors to terms running to the 2029 annual meeting and on ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Holders of common stock as of the May 7, 2026 record date, with one vote per share, may vote online, by phone, mail, or during the webcast. There were 78,520,587 shares of common stock outstanding as of April 24, 2026. The board recommends voting FOR all director nominees and FOR auditor ratification. The proxy also details board committee structure, director independence, non-employee director fees and option grants, and executive pay, including salaries, equity awards, and change-in-control severance terms for senior leaders.
Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026. She will serve until the company’s 2028 annual meeting of stockholders and has also been named to the company’s Science and Technology Committee.
Dr. Sepp-Lorenzino brings extensive experience from leadership and scientific roles at multiple biotechnology and pharmaceutical companies and currently leads a consulting firm focused on genomic medicine. Under Lexeo’s non-employee director compensation policy, she will receive $40,000 in annual cash compensation and an initial option to purchase 50,000 shares, with future annual option grants of 25,000 shares beginning with the 2027 annual meeting.
Lexeo Therapeutics ownership disclosure: Suvretta Capital Management, LLC reports shared beneficial ownership of 5,674,778 shares (7.7%) of common stock, and Averill Master Fund, Ltd. reports shared beneficial ownership of 4,827,730 shares (6.5%). Aaron Cowen is reported with shared beneficial ownership of 5,674,778 shares (7.7%). The schedule states these securities are directly owned by advisory clients of Suvretta and includes a joint filing agreement and control-person identification.
Lexeo Therapeutics, Inc. Chief Executive Officer Richard Nolan reported an open-market sale of 55,000 shares of common stock at a weighted average price of $5.6934 per share. The sale on April 6, 2026 was made under a pre-arranged Rule 10b5-1 trading plan.
Following this transaction, Nolan directly holds 340,106 shares of Lexeo common stock, which includes 261,349 Restricted Stock Units that may convert into shares if vesting conditions are satisfied.
Lexeo Therapeutics files its annual report detailing a clinical-stage genetic medicine pipeline focused on cardiovascular and neurodegenerative diseases. The company is advancing AAVrh10-based gene therapies, led by LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2‑arrhythmogenic cardiomyopathy.
Interim Phase 1/2 data for LX2006 show increased cardiac frataxin expression and meaningful improvements in cardiac structure, biomarkers and neurologic function, supported by multiple FDA designations and alignment on a registrational SUNRISE‑FA 2 study. LX2020 has demonstrated dose‑dependent PKP2 protein restoration and reduced arrhythmia burden in PKP2‑ACM patients. As of June 30, 2025, non‑affiliate equity market value was approximately $216.5 million, and 74,087,063 common shares were outstanding as of March 27, 2026.
Lexeo Therapeutics reported fourth quarter and full year 2025 results and detailed progress across its cardiac gene therapy pipeline. The company ended December 31, 2025 with cash, cash equivalents and investments of $246.6 million, which it believes will fund operations into 2028.
For 2025, research and development expenses were $63.8 million, down from $74.1 million in 2024, while general and administrative expenses rose to $45.5 million from $31.7 million, reflecting growth investments. Net loss for 2025 was $100.0 million, or $1.86 per share, broadly similar to 2024.
Operationally, Lexeo advanced lead programs LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2 arrhythmogenic cardiomyopathy, including positive interim data, FDA alignment on the SUNRISE‑FA 2 pivotal trial design, and preparation for a Biologic License Application for LX2006. The company also highlighted a research collaboration with Johnson & Johnson on targeted cardiac delivery of AAV gene therapy and a previously executed $154 million equity financing to support its expanding cardiovascular pipeline.